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Abstract
Given the significant increases in the incidence of metabolic diseases, efficient strategies for preventing and treating
of these common disorders are urgently needed. This includes the development of phytopharmaceutical products or
functional foods to prevent or cure metabolic diseases. Plant extracts from edible biomaterial provide a potential
resource of structurally diverse molecules that can synergistically interfere with complex disorders. In this study we
describe the safe application of ethanolic chamomile (Matricaria recutita) flowers extract (CFE) for the treatment and
prevention of type 2 diabetes and associated disorders. We show in vitro that this extract activates in particular
nuclear receptor peroxisome proliferator-activated receptor gamma (PPARγ) and its isotypes. In a cellular context, in
human primary adipocytes CFE administration (300 µg/ml) led to specific expression of target genes of PPARγ,
whereas in human hepatocytes CFE-induced we detected expression changes of genes that were regulated by
PPARα. In vivo treatment of insulin-resistant high-fat diet (HFD)-fed C57BL/6 mice with CFE (200 mg/kg/d) for 6
weeks considerably reduced insulin resistance, glucose intolerance, plasma triacylglycerol, non-esterified fatty acids
(NEFA) and LDL/VLDL cholesterol. Co-feeding of lean C57BL/6 mice a HFD with 200 mg/kg/d CFE for 20 weeks
showed effective prevention of fatty liver formation and hepatic inflammation, indicating additionally hepatoprotective
effects of the extract. Moreover, CFE treatment did not reveal side effects, which have otherwise been associated
with strong synthetic PPAR-targeting molecules, such as weight gain, liver disorders, hemodilution or bone cell
turnover. Taken together, modulation of PPARs and other factors by chamomile flowers extract has the potential to
prevent or treat type 2 diabetes and related disorders.
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Introduction
Metabolic disorders such as type II diabetes and obesity
show strikingly increasing global incidences, with more than
200 million people suffering from diabetes and more than 1
billion overweight or obese people worldwide [1]. These
common diseases are not restricted to Western societies, but
cumulatively affect people in newly industrializing countries [2].
In addition to associated comorbidities such as atherosclerosis,
dyslipidemia, and cancer, metabolic disorders have a huge
impact on the quality of life and the public health systems, and
require novel approaches for effective prevention and
treatment. Dietary and lifestyle interventions may efficiently
counteract the cumulative development of metabolic
disturbances, for example by early complementation with safe
preventive phytopharmaceuticals or application of tailored food
supplements [3].
Peroxisome proliferator-activated receptors (PPARs) are a
family of nuclear receptors that can be activated by binding of
various natural molecules including a number of dietary small
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molecules [4]. The gene-regulating PPARs play a central role
in differentiation and glucose and lipid homeostasis, and can
suppress inflammatory processes [5]. Pharmacologic
modulation of PPARs is a common strategy to treat insulin
resistance and dyslipidemia [5]. Three different subtypes of
PPAR exist, PPARα, PPARβ/δ and PPARγ. These nuclear
receptors are expressed in many different cell types [6].
PPARα, predominantly expressed in liver, controls fatty acid
oxidation and lipoprotein metabolism, and is further involved in
gluconeogenesis and ketone body biosynthesis. PPARβ/δ is
ubiquitously expressed and has a central role in fatty acid
oxidation and adaptive thermogenesis. PPARγ is highly
expressed in adipocytes, but further controls differentiation and
metabolic processes in liver, macrophages, bone cells and
skeletal muscle. PPARγ is a key player in adipose tissue
differentiation and maintenance by regulating energy storage
and balance. This nuclear receptor is involved in glucose
metabolism by regulating insulin sensitivity and represents a
potent target for the treatment of diabetes [7]. Due to its large,
hydrophobic binding pocket [4], PPARγ has been shown to
mediate effects of dietary lipids and related small molecules. In
general, to maintain cell homeostasis and physiology the
PPARs play various, in part synergistic roles as environmental
and nutrient sensors [8]. However, the activation of PPARγ
requires decent fine-tuning to avoid potential side-effects as
are for example known from synthetic antidiabetic compounds
such as the thiazolidinediones. Due to strong but unspecific
activation of PPARγ-directed gene expression in various
tissues the thiazolidinediones induced liver diseases, weight
gain, oedema, heart failure, osteoporosis, and cancer [9,10].
Selective PPAR modulators (SPPARMs) that maintain the
antidiabetic potential of full PPARγ agonists but minimise
potential side effects are promising for developing antidiabetic
and antihyperlipidemic molecules with acceptable safety
profiles [11-13]. Concerted activation of two or all three
mentioned PPAR subtypes has further been proposed as an
alternative, synergistic therapeutic approach [14].
Plant extracts provide an interesting resource for prevention
and therapy of diverse diseases. The development of most
established drugs is historically based on the identification of
phytopharmaceuticals [15]. In addition, whole extracts or
subfractions of various biomaterials are still a major medicinal
application worldwide (e.g. by Traditional Chinese Medicine)
[16], and have become a major focus of nutritional research to
develop functional food and nutraceuticals with health benefits
and good safety profiles [17].
Here we report the identification of ethanolic chamomile
(Matricaria recutita) flowers extract as a phytopharmaceutical
mixture to activate PPARγ resulting in considerable therapeutic
effects on type 2 diabetes and dyslipidemia in insulin-resistant
high-fat diet (HFD)-fed mice. The chamomile flowers extract
further showed potent prevention of associated fatty liver
disease without adverse side effects of classical PPAR
agonists.
Materials and Methods
Compounds were purchased from the following sources:
rosiglitazone (Cayman Chemical, Ann Arbor, MI, USA),
GW7647, GW0742 (Sigma-Aldrich, Taufkirchen, Germany).
The chamomile flowers extract (CFE) used is a standardized
[18] hydroethanolic (30% v/v) extract, which was provided by
Steigerwald Arzneimittelwerk GmbH (Darmstadt, Germany) as
a lyophilised powder. Main substance classes and
approximative number of secondary phytochemical compounds
for the CFE have recently been described [19].
PPAR binding and transcriptional activation assays
Initially, we analysed the nine plant extracts of the widely
used product Iberogast (STW5) [19]. CFE turned out to be a
very efficient in activating PPARs as detected by time-resolved
fluorescence resonance energy transfer (TR-FRET) - based
assays according to the manufacturer’s protocol (Lanthascreen
PPAR alpha/gamma/delta Competitive Binding Assay Kits, Life
Technologies, CA, USA) as described recently [20].
Transcriptional activation of PPARs was assessed in cellular
reporter gene assays according to the manufacturer’s protocols
(GeneBLAzer PPAR alpha/gamma/delta Assay, Life
Technologies). Briefly, HEK 293 cells were stably expressing a
GAL4-PPAR-LBD fusion protein and an UAS-beta-lactamase
reporter gene. Cells were incubated with different
concentrations of compounds resulting in differential
expression of the reporter gene. Binding and activation assays
were measured with the POLARstar Omega (BMG LABTECH,
Offenburg, Germany). Data were fitted using GraphPad Prism
5.0 according equation: Y=Bottom + (Top-Bottom)/
(1+10^((LogEC50-X)*HillSlope)) with variable Hill slope.
Cell culture
Primary subcutaneous preadipocytes (Zen-Bio, Research
Triangle Park, NC, USA) were differentiated as described
recently [20]. Adipocytes were treated for 24 h with 300 µg/ml
chamomile flowers extract (CFE), 10 µM rosiglitazone (RGZ) or
vehicle only. Human HepG2 cells (ATCC) were cultivated in
DMEM (Gibco, Life Technologies) supplemented with 10%
FBS and were treated for 24 h with 300 µg/ml chamomile
flowers extract (CFE), 10 µM GW7647 or vehicle only.
Viability was assessed in HepG2 cells treated with CFE for
24 h using the CellTiter-Glo Luminescent Cell Viability Assay
(Promega, Mannheim, Germany) according to the
manufacturer’s protocol.
PPAR knockdown
Specificity of PPARγ-driven modulation of gene expression
in adipocytes was investigated using siRNA-mediated
knockdown and subsequent real-time PCR detection.
Therefore, differentiated human adipocytes were seeded in 24-
well-plates (Nunc, Thermo Fisher Scientific, Langenselbold,
Germany) at a confluence of 30 to 60%. Cells were transfected
with 10 nM PPARγ Silencer Select siRNA (ID s10888) or 10
nM Silencer Select Negative Control 1 siRNA (all Life
Technologies) using DeliverX Plus siRNA Transfection Kit
(Panomics, Vignate-Milano, Italy). Transfection was carried out
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in serum- and antibiotic-free AM-1 medium (AM-1-PRF-SF,
Zen-Bio) for 4 h and continued for 3 days in standard AM-1
medium. Afterwards, cells were treated with 300 µg/ml CFE, 10
µM RGZ or vehicle control for 24 hours prior to RNA collection.
Specificity of PPARα-driven modulation was investigated in
siRNA-mediated knockdown in human hepatocytes and
subsequent real-time PCR detection. Therefore, HepG2 cells
were seeded in 24-well-plates (Nunc) at a density of 40,000
cells per well. Cells were transfected with 30 nM PPARα
Silencer Select siRNA (ID s10880) or 30 nM Silencer Select
Negative Control 1 siRNA (all Life Technologies) using the
TransIT-TKO Transfection Reagent (Mirus Bio, WI, USA)
according to the manufacturer’s protocol. Transfection was
performed for 2 days, and cells were then treated with
300 µg/ml CFE, 10 µM GW7647 or vehicle control for
additional 24 hours prior to RNA collection.
RNA purification, cDNA synthesis and quantitative real-
time PCR
Animal tissues (pool of 2 mice/group) were first lysed and
homogenized in TRIzol (Life Technologies) using 5 mm steel
beads at 20 Hz for 8 min (TissueLyser, QIAGEN, Hilden,
Germany), and isolation of total RNA was done according to
the manufacturer’s instruction. Subsequent RNA purification
was performed using the RNeasy Mini Kit (QIAGEN) and
genomic DNA digestion (DNase-Set, QIAGEN) according to
the manual. Total RNA of cell cultures samples was isolated
using the RNeasy Mini Kit only. The concentration of extracted
RNA was measured using the Nanodrop ND-1000
Spectrophotometer (Thermo Fisher Scientific). RNA was
reversely transcribed into cDNA applying the High Capacity
cDNA Reverse Transcription Kit (Life Technologies) with
random primers. Quantitative PCR was carried out on the ABI
Prism 7900HT Sequence Detection System using the SYBR
Green PCR Master Mix (all Life Technologies). After an initial
denaturation at 95 °C for 10 min, the cDNA was amplified by 40
cycles of PCR (95 °C, 15 s; 60 °C, 60 s). The relative gene
expression levels were normalized using β-actin gene and
quantified by the 2‑ΔΔCt method [21]. Primer sequences are
summarised in Table 1.
Animals and diets
Animal studies were approved by the State Office of Health
and Social Affairs (Berlin, Germany) and were carried out
according internationally approved guidelines. All animals were
singly housed under temperature-, humidity- and light-
controlled conditions (22°C, 50% humidity, 12 h light/12 h dark
cycle). Mice had ad libitum access to food and water. Mice,
food and water were weighed in a regularly to determine
changes in body weight and food and water intake. Low-fat diet
(LFD, D12450B, 10 kcal% fat, 18.0 MJ/kg, ssniff, Soest,
Germany) was composed as follows: 4.1% crude fat, 18.1%
crude protein, 26.6% starch, 35.5% sugar/dextrines, 4.7%
crude fibre. High-fat diet (HFD, D12492, 60 kcal% fat, 25.3
MJ/kg, ssniff) was composed as follows: 34.0% crude fat,
24.1% crude protein, 1.1% starch, 23.8% sugar/dextrines,
6.0% crude fibre.
Two different mice studies were performed. For the
prevention study, lean male 8 week-old C57BL/6 mice were
weighed and distributed equally to three groups (n=14 each)
and were fed over 20 weeks with either a LFD, HFD or HFD
with 200 mg/kg/d CFE. Therefor, lyophilised CFE was diluted in
drinking water (1.1-2.3 mg/ml depending on body weight).
Blood was taken from the submandibular or tail vein of
conscious mice for testing of blood parameters before dosing
and after 6, 12, 17 and 20 weeks. After 20 weeks of dosing,
fasted mice were killed by cervical dislocation and tissues were
stored at -80 °C before use.
For the therapy study, we subjected male 6-week old
C57BL/6 mice to an HFD for 18 weeks to induce obesity and
insulin resistance. Prior to compound treatment, mice were
weighed and distributed uniformly to three groups (n=9-14
each). Mice were fed over 6 weeks with an HFD without
compound (vehicle), with 4 mg/kg/d (34 µg/ml) rosiglitazone
(RGZ) or with 200 mg/kg/d (2.3 mg/ml) CFE diluted in drinking
water. After 2 weeks of treatment mice were subjected to an
oral glucose tolerance test (OGTT). After 6 weeks of dosing,
fasted mice were killed by cervical dislocation. Hematocrit was
measured by weighting of blood samples before and after
plasma separation and is presented as wt/wt %.
Oral glucose tolerance test (OGTT)
Mice were fasted overnight before being subjected to an oral
glucose (Sigma-Aldrich) dose of 2 g/kg body weight. Blood was
taken from the tail vein at the indicated time points and blood
glucose was analysed in a Hemocue B-Glucose analyser
(Hemocue, Großostheim, Germany). Whole blood was further
collected using Microvette lithium-heparin coated capillary
tubes (CB300, Sarstedt, Nürnbrecht, Germany). After
centrifugation for 5 min at 2000 g at 4°C, plasma was collected
and stored at -80°C for subsequent measurements of insulin.
Metabolic parameters measurements
Whole blood glucose was analysed in a Hemocue B-Glucose
analyser. Plasma glucose was measured using the Amplex
Red Glucose Assay Kit (Life Technologies). Plasma
triacylglycerol, NEFA, HDL and LDL/VLDL cholesterol and
plasma alanine transaminase (ALT) were determined with
colorimetric quantification kits (Biovision, Milpitas, CA, USA).
Insulin (Insulin Ultrasensitive EIA, ALPCO, Salem, NH, USA),
and osteocalcin (BGLAP bone gamma-carboxyglutamate (gla)
protein, ABIN415574, antibodies-online, Aachen, Germany)
were determined in plasma samples using ELISA. TNFα,
triacylglycerol and NEFA in liver tissues were analysed as
described recently [20]. All assays were performed according
to the manufacturer’s instructions.
Homeostasis model assessment of insulin resistance
(HOMA-IR) was determined according to HOMA-IR = fasting
blood glucose (mg/dl) × fasting insulin (µU/ml)/405.
Statistical Analyses
Data are presented as mean ± standard error of mean (SEM)
if not otherwise denoted. Statistical tests were performed in
GraphPad Prism 5.0. For comparison of CFE- and vehicle-
treated samples statistical significance was examined by
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Table 1. Primer sequences used for quantitative real-time PCR.
Symbol Gene ID Forward primer Reverse primer
ACTB 60 CAGCCATGTACGTTGCTATCCAGG AGGTCCAGACGCAGGATGGCATG
CD36 948 GTTGATTTGTGAATAAGAACCAGAGC TGTTAAGCACCTGTTTCTTGCAA
FABP4 2167 GGTGGTGGAATGCGTCATG CAACGTCCCTTGGCTTATGC
LPL 4023 ACAGAATTACTGGCCTCGATCC CTGCATCATCAGGAGAAAGACG
NR1H3 (LXRα) 10062 CACCTACATGCGTCGCAAGT GACAGGACACACTCCTCCCG
PDK4 5166 CTGGACTTTGGTTCAGAAAATGC CCTTCAGAATGTTGGCGAGTCT
PLTP 5360 GACACCGTGCCTGTGCG GGTGGAAGCCACAGGATCCT
PPARA 5465 TTGCTGTGGAGATCGTCCTG CCGGGTGGTTGCTCTGC
PPARG 5468 CATGGCAATTGAATGTCGTGTC CCGGAAGAAACCCTTGCAT
SCD 6319 TGCCCACCTCTTCGGATATC TAGTTGTGGAAGCCCTCACCC
SLC27A4 (FATP4) 10999 CCCCCTCTACCACTCAGCAG TTCTTCCGAATCACCACCGT
ACADM 34 TAATTGGTGACGGAGCTGGTTT CAACAGCACCAGCAGCTACTACA
ACOX2 8309 TGATCAAACAGACAATGGCTTCC GCAAGACCTGTGCAAAGCG
CPT 2 1376 GAGTTTTGAAAATGGGATTGGAA AACCAGGGTCCCGAAATGTAG
ECH1 1891 TGCTCAGAGAGTTTCAGATCAACC CTGTCCATGTTGGGCAAGCT
HMGCS2 3158 CTAGCCTCCCGAAAGTGTGT GGTGGGGAGAAATTCACCTT
Acadl 11363 AGCCTGGGGCTGGAAGTGACTTA CACGGTTGGTGACGGCCACG
Acadm 11364 ACGGGGGAAAGGCCAACTGGTAT AGGATCTGGGTTAGAACGTGCCA
Acly 104112 CAGCCAAGGCAATTTCAGAGC CTCGACGTTTGATTAACTGGTCT
Acox1 11430 CAGCACTGGTCTCCGTCATG CTCCGGACTACCATCCAAGATG
Actb 11461 TGTCCACCTTCCAGCAGATGT AGCTCAGTAACAGTCCGCCTAGA
Adipoq 11450 AGGAAAGGAGAGCCTGGAGA CGAATGGGTACATTGGGAAC
Apoa2 11807 GACTGCAGCACAGAATCGCAGCA CCAGCAGTGCGACCATTGCGA
Apoc3 11814 CGTAGGTGCCATGCAGCCCC CAGCTCGGGCAGATGCCAGG
Ccl11 20292 AGAGCTCCACAGCGCTTCTA GGAAGTTGGGATGGAGCCTGG
Ccl3 20302 GCTCCCAGCCAGGTGTCATTTTCC GGGGTTCCTCGCTGCCTCCA
Ccl5 20304 CTCACTGCAGCCGCCCTCTG CCGAGCCATATGGTGAGGCAGG
Ccr2 12772 TCAGCTGCCTGCAAAGACCAGA CGGTGTGGTGGCCCCTTCAT
Ccr5 12774 AGACTCTGGCTCTTGCAGGATGGA GGCAGGAGCTGAGCCGCAAT
Cd36 12491 GCTTGCAACTGTCAGCACAT GCCTTGCTGTAGCCAAGAAC
Cd40 1678 CGGCGTTCACTGTAAGGAGT GTTTTCTGCCCCACCTGCTA
Cd80 1701 ATACGACTCGCAACCACACC GAGGGTCTTCTGGGGGTTTT
Cd86 2539 ACTGTCAGTGATCGCCAACT TAGGTTTCGGGTGACCTTGC
Cpt 1a 12894 TCTGCAGACTCGGTCACCACTCAAG GGCTCAGGCGGAGATCGATGC
Cpt 2 12896 AAGCAGCGATGGGCCAG GAGCTCAGGCAGGGTGACC
Cxcl1 14825 GGCCCCACTGCACCCAAACC CAAGGCAAGCCTCGCGACCA
Fabp4 11770 CATGGCCAAGCCCAACAT CGCCCAGTTTGAAGGAAATC
Hsd11b1 15483 CAGCCTCTGCTCACTACATTGC AGTCCGCCCATGAGCTTTC
Ifi30 65972 GTCAGCTGTACCAGGGAACG GTCTGGGCTTTGTGGGACAT
Ifit3 15959 GATTTCTGAACTGCTCAGCCC ATTCCCGGTTGACCTCACTCA
Il27ra 50931 AGGCCAGGCTACTCACTACA GGGTTTGACTGCTCACGTTC
Irak4 266632 ACAGCGACAACCTGTGCTTA GTGTACCATCCAGGCAGGAC
Irf5 27056 CCCTGTCCCAGACCCAAATC AGGTCCGTCAAAGGCAACAT
Lgals3 16854 TGGGGCCTACCCCAGTGCTC GGCACCGTCAGTGGTCCAGC
Nr1h3 (Lxrα) 22259 GCTCTGCTCATTGCCATCAG TGTTGCAGCCTCTCTACTTGGA
Pck1 18534 ATCATCTTTGGTGGCCGTAG CATGGCTGCTCCTACAAACA
Ppargc1a 19017 TCCCATACACAACCGCAGTCGC GGGGTCATTTGGTGACTCTGGGGT
Ppargc1b 170826 GGGAAAAGGCCATCGGTGAA CAGCACCTGGCACTCTACAA
Ptgs2 19225 CCCTGCTGCCCGACACCTTC CCAGCAACCCGGCCAGCAAT
Tirap 117149 CTTCATCCTCCTCCGTCCCA TGCCTGAACCAGTCAGCTATC
Tlr2 24088 AACCTCAGACAAAGCGTCAA TCCTGAGCAGAACAGCGTTT
Tlr5 53791 GAATCCCGCTTGGGAGAACA TTCCAAGCGTAGGTGCTCTG
Tlr6 21899 AGTGCTGGAAATAGAGCTTGGA TATTAAGGCCAGGGCGCAAA
Tlr7 170743 AAGAAAGATGTCCTTGGCTCCC TCAAGAGGTCTGGTGGAGGA
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unpaired Student’s t-test if not otherwise stated. A p value ≤
0.05 was defined as statistically significant.
Results
CFE contains selective PPAR modulators (SPPARMs)
and particularly activates PPARγ
Initially, binding of PPARs by small molecules from the
ethanolic chamomile flowers extract (CFE) was analyzed using
a time-resolved fluorescence resonance energy transfer (TR-
FRET)-based competitive binding assay. Titration of the
PPARγ ligand-binding domain with CFE revealed an overall
binding affinity constant (Ki) of 6 µg/ml (Figure 1A and Table 2).
In a reporter gene assay, CFE induced partial PPARγ
activation with a half-maximal effective concentration (EC50) of
86 µg/ml and with a maximal potency of 26% (Figure 1B)
compared to rosiglitazone (RGZ). CFE additionally contains
natural products that bound and activated PPARα (Ki = 10
µg/ml, EC50 = 3750 µg/ml, Figure 1C,D) and PPARβ/δ (Ki = 9
µg/ml, EC50 = 1204 µg/ml Figure 1E, F and Table 2).
These results suggested that the ethanolic extract from
chamomile flowers contain selective PPAR modulators
(SPPARMs), which particularly activate PPARγ and,
additionally - but with about at least one order of magnitude
lower half-maximal effective concentration (EC50) – the isotypes
PPARα and β/δ. This extract may thus modulate gene
expression in PPAR-expressing target cells.
CFE activates PPARγ in human primary adipocytes
Activation of PPARγ, in particular in adipocytes, is a well-
established strategy for antidiabetic treatment [22]. In
accordance with partial PPARγ activation in the reporter gene
assay, CFE-treated human primary adipocytes showed
increased expression of PPARγ target genes such as the fatty
acid binding protein 4 (FABP4), the fatty acid transport protein
4 (FATP4) or the liver X receptor alpha (LXRa or NR1H3)
(Figure 2A). Whereas FABP4 expression is a marker of
adipocyte differentiation and lipid accumulation [23], FATP4
facilitates fatty acid uptake by the adipocytes, and LXRα is a
mediator of antiinflammatory gene expression [24]..
Noteworthy, the increase in FABP4 expression was 10-fold
less with CFE as with RGZ (Figure 2A), indicating less
induction of adipogenesis, a process that might be associated
with body weight gain in vivo. Knockdown of PPARγ in these
cells by siRNA led to a significant reduction of CFE-induced
gene expression (Figure 2B), indicating specific modulation of
PPARγ-derived transcription in adipocytes by CFE.
CFE activates PPARα in human hepatocytes
Activation of PPARα that is in particular highly expressed in
liver, is a well-established strategy for treating metabolic
diseases including fatty liver, which can systemically also have
beneficial effects on insulin sensitivity [25]. We thus determined
expression of target genes of PPARα in HepG2 liver cells.
Similarly to the PPARα agonist GW7647, CFE treatment
significantly induced expression of genes responsible for fatty
acid β-oxidation such as the acyl-CoA oxidase 2 (ACOX2), the
carnitine palmitoyltransferase 2 (CPT 2) and the enoyl CoA
hydratase 1 (ECH1), and of the ketogenic HMG-CoA synthase
2 (HMGCS2) gene (Figure 2C). Knockdown of PPARα in
HepG2 cells diminished the CFE-induced gene expression
(Figure 2D), indicating that in liver cells CFE mediates gene
expression of PPARα target genes.
CFE shows antidiabetic effects in insulin-resistant
obese DIO mice
In general, activation of PPARγ in adipocytes can lead to
strong antidiabetic effects in an in vivo context. To investigate
these effects of CFE in a common mouse model of insulin
resistance, we treated obese HFD-fed C57/BL6 mice for 6
weeks with 200 mg/kg/d CFE, 4 mg/kg/d rosiglitazone (RGZ) or
vehicle only through the drinking water. After 2 weeks of
dosage CFE-treated mice featured considerably reduced the
fasting blood glucose (13% decrease vs. vehicle, p=0.007)
equally to the established antidiabetic drug RGZ (Figure 3A).
CFE furthermore reduced fasting plasma insulin levels (23%
decrease, p=0.02, Figure 3B). Although primarily developed for
human clinical data, homeostatic model assessment of insulin
resistance (HOMA-IR) is a common approach for estimating
the progress of insulin resistance also in murine models [26].
Thus, CFE decreased the HFD-induced insulin resistance by
36% (p=0.01, Figure 3C), which was half as potent as RGZ
(67% decrease, Figure 3C).
We further investigated insulin resistance using oral glucose
tolerance tests (OGTT) by kinetically following the metabolic
clearance of a standard glucose load (2 g/kg). CFE-treated
mice revealed increased glucose clearance (Figure 3D) and
concomitantly reduced insulin release (Figure 3E) after 2
Table 1 (continued).
Symbol Gene ID Forward primer Reverse primer
Tnf 21926 AGCCCACGTCGTAGCAAACCA CATGCCGTTGGCCAGGAGGG
Tnfaip2 3590 GATTCTCTGAACCGCCTGCT TAAACAGCGGCTTCAGGTCC
Tnfaip3 4352 CCTGCCCAGGAGTGTTACAG CGCGAAGTTCAGGTCCACT
Tollip 54473 GGATGACCGCATAGCTTGGA CTGGGAGGGACGTGTAGGA
Ucp1 22227 CACGGGGACCTACAATGCTT TAGGGGTCGTCCCTTTCCAA
Ucp2 22228 CGCCTTCTACAAGGGGTTCA CGAGATTGGTAGGCAGCCAT
Ucp3 22229 ACAAAGGATTTGTGCCCTCC TCAAAACGGAGATTCCCGCA
doi: 10.1371/journal.pone.0080335.t001
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Figure 1.  Binding and transcriptional activation of PPARs by natural-products contained in camomile flowers extract
(CFE).  (A, B) PPARγ bound and activated by CFE (µg/ml) or rosiglitazone (nM). (C, D) PPARα bound and activated by CFE (µg/ml)
or GW7647 (nM). (E,F) PPARβ/δ bound by CFE (µg/ml) or GW0742 (nM). Binding of compounds was measured in a competitive
time-resolved fluorescence resonance energy transfer assay. Transcriptional activation was determined in a reporter gene assay
and is represented relative to the reference compound. Data are expressed as mean ± SD (n=3-4).
doi: 10.1371/journal.pone.0080335.g001
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weeks of treatment. As observed for basal metabolic levels
(Figures 3A-C), CFE alleviated HFD-induced insulin resistance
half as effective as RGZ, indicating considerable antidiabetic
effects of this plant extract.
To investigate the role of PPARγ activation in vivo, we
analysed the expression of PPARγ target genes in the visceral
white adipose tissue (WAT) of these mice (Figure S1). CFE
activated transcription of important genes involved in lipid
metabolism, such as the PPARγ coactivator 1 alpha and beta
(Ppargc1a and Ppargc1b), the uncoupling protein 1 (Ucp1), the
ATP citrate lyase (Acly) and the phosphoenolpyruvate
carboxykinase 1 (Pck1), suggesting regulation of adipose
tissue lipid metabolism similar to RGZ (Figure S1A).
Type 2 diabetes seems to be causally linked to adipose
tissue inflammation [27]. As shown in Figure S1B, we also
measured in the WAT of treated mice the expression of a panel
of HFD-induced genes involved in inflammation [20,28].
However, gene expression of inflammatory markers remained
largely unchanged with either RGZ or CFE treatment.
CFE considerably improves dyslipidemia in obese DIO
mice
Dyslipidemia is another important feature of metabolic
diseases, which can be inhibited by activation of PPARs [29].
During 6 weeks CFE strongly decreased the HFD-induced rise
in the fasting plasma concentrations of non-esterified fatty
acids (NEFA) by 53% (Figure 4A) and further reduced the
plasma triacylglycerol gain by 35% (Figure 4B) comparable to
the strong synthetic PPARγ agonist RGZ. In contrast to RGZ,
CFE-fed mice also showed reduced plasma levels of total
cholesterol (16% decrease) and LDL/VLDL cholesterol (43%
decrease). Thus, additional amelioration of HFD-induced
hypercholesterolemia by the CFE might be achieved, at least in
part, through activation of PPARα (Figure 4C).
Table 2. PPAR binding and activation data of chamomile
flowers extract (CFE) and reference compounds.
Receptor Parameter CFE RGZ GW7647 GW0742
PPARα Ki (µg/ml or nM) 10 n.d. 13 n.d.
 EC50 (µg/ml or nM) ≈ 3750 n.d. 0.2 n.d.
 Efficacy (%) n.d. n.d. 100 n.d.
PPARβ/δ Ki (µg/ml or nM) 9 n.d. n.d. 3
 EC50 (µg/ml or nM) 1204 n.d. n.d. 0.2
 Efficacy (%) n.d. n.d. n.d. 100
PPARγ Ki (µg/ml or nM) 6 12 n.d. n.d.
 EC50 (µg/ml or nM) 86 4 n.d. n.d.
 Efficacy (%) 26 100 n.d. n.d.
CFE is presented in µg/ml, RGZ, GW7647 and GW0742 are given in nM. CFE,
camomile flowers extract (µg/ml). RGZ, rosiglitazone (nM). n.d, not determined.
doi: 10.1371/journal.pone.0080335.t002
CFE prevents insulin resistance, non-alcoholic fatty
liver disease (NAFLD) and hepatic inflammation in
long-term treated HFD-fed mice
To test potential effects of preventive administration of CFE
on metabolic disorders we fed healthy C57BL/6 mice for 20
weeks with either a LFD, a HFD or a HFD with simultaneous
CFE administration (200 mg/kg/d). Similar to the therapeutic
study, CFE inhibited the HFD-induced rise in plasma glucose
and the associated formation of insulin resistance by 35%, as
assessed by HOMA-IR (Figures 5A-C). Furthermore, CFE
partly stopped the increase in plasma NEFA and
triacylglycerols (Figures 5D-E), corroborating the above
described effects observed in short-term treated DIO mice
(Figures 3-4).
Moreover, HFD-feeding over 20 weeks resulted in
considerably elevated plasma levels of alanine transaminase
(ALT), indicating liver damage due to steatohepatitis. CFE-
treatment strikingly prevented this raise in plasma ALT levels
by 64% (p=0.05, Figure 6A). Examination of the liver tissues
clearly showed reduced formation of fatty liver of CFE-treated
mice (Figure 6B), which was accompanied by reduced liver
triacylglycerols (72% decrease, Figure 6C) and liver NEFA
concentrations (64% decrease, Figure 6D). Consistently, HFD-
feeding resulted in a boost of protein expression of pro-
inflammatory tumor necrosis factor alpha (TNFα) that was
significantly prevented by application of CFE by 54% (Figure
6E). Analyses of liver gene expression consistently showed
induction of fatty acid oxidation, e.g. through Cpt 2, medium
and long-chain acyl-Coenzyme A dehydrogenase (Acadm and
Acadl), and Ppargc1a (Figure 6F). Furthermore, CFE
completely prevented the HFD-induced raise of inflammatory
transcripts in the liver (Figure 6G). These results indicate that
early administration of CFE effectively protects from HFD-
induced fatty liver disease and associated liver inflammation.
CFE does not induce the adverse side-effects
associated with PPARγ-activating thiazolidinediones
CFE has been used as a safe extract for various therapeutic
applications [30]. Consistently, in vitro viability assays did not
indicate significant toxicity effects up to 800 µg/ml CFE (Figure
7A). Adverse body weight gain is a frequent side effect of
PPARγ activation by rosiglitazone. However, CFE-treated mice
did not show any body weight changes compared to untreated
mice, neither during treatment for 6 weeks (Figure 7B) nor
during long-term treatment (Figure 7C). At the same time, CFE
treatment did not change food consumption of the mice (Figure
7D and E). CFE treatment did also not impair hematocrit levels
(an indicator of fluid retention and potential cardiovascular
complications) in DIO mice (Figure 7F), however, in our hands
RGZ-treated mice did not show any signs of fluid retention after
6 weeks of treatment as we have shown recently [31]. Another
well-known side-effect of synthetic PPARγ agonists is the
impairment of osteoblastogenesis leading to osteoporosis and
increased fracture risk. In HFD-fed mice, CFE-treated DIO
mice did not show any change in plasma bone osteocalcin
levels (Figure 7G), indicating no adverse effects on bone cell
turnover with CFE, contrary to RGZ-treated mice [31]. These
various results suggest that administration of chamomile
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Figure 2.  Gene expression profile of camomile flowers extract (CFE) in human adipocytes and hepatocytes.  (A) Human
primary adipocytes were treated with either 10 µM RGZ, 300 µg/ml CFE or vehicle only for 24 h. Gene expression was analyzed by
qPCR. (B) Human primary adipocytes were transfected with PPARγ siRNA (hatched bars) or control siRNA (unhatched bars) and
were treated with either 10 µM RGZ, 300 µg/ml CFE or vehicle only for 24 h. (C) Human HepG2 hepatocytes were treated with
either 10 µM GW7647, 300 µg/ml CFE or vehicle only for 24 h and gene expression was analyzed by qPCR. (D) Human HepG2
hepatocytes were transfected with PPARα siRNA (hatched bars) or control siRNA (unhatched bars) and were treated with either 10
µM GW7647, 300 µg/ml CFE or vehicle only for 24 h. Data are expressed as mean ± SEM (n=2-4/group). n.s. not significant,
*p≤0.05, **p≤0.01, ***p≤0.001 vs. vehicle. RGZ, rosiglitazone ; CFE, camomile flowers extract; GW, GW7647.
doi: 10.1371/journal.pone.0080335.g002
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flowers extracts does not induce the typical side effects of
highly efficient synthetic PPARγ agonists.
Figure 3.  Antidiabetic effects of camomile flowers extract in insulin-resistent DIO mice.  (A) Fasting blood glucose of
untreated HFD-fed mice or mice treated for 2 weeks with RGZ or CFE. (B) Fasting plasma insulin after 2 weeks of treatment. (C)
Effect of treatment for 2 weeks on insulin resistance determined by homeostatic model assessment of insulin resistance (HOMA-IR).
(D, E) Glucose and insulin concentrations during oral glucose tolerance test (OGTT) after 2 weeks of treatment with vehicle, RGZ or
CFE. AUC, area under the curve. Data are expressed as mean ± SEM. *p≤0.05, **p≤0.01 vs. vehicle-treated HFD-fed mice. HFD,
high-fat diet; VEH, vehicle (n=13-14); RGZ, rosiglitazone (n=8-14) ; CFE, camomile flowers extract (n=12-14).
doi: 10.1371/journal.pone.0080335.g003
Figure 4.  Camomile flowers extract improves dyslipidemia in obese DIO mice.  (A) Fasting plasma NEFA after 6 weeks of
treatment. (B) Fasting plasma triacylglycerol after 6 weeks of treatment. (C) Fasting plasma total, HDL and LDL/VLDL cholesterol in
DIO mice after 6 weeks of treatment. Data are expressed as mean ± SEM. *p≤0.05, **p≤0.01, ***p≤0.001, n.s. not significant vs.
vehicle-treated HFD-fed mice. LFD, low-fat diet; HFD, high-fat diet; VEH, vehicle (n=13-14); RGZ, rosiglitazone (n=8-14) ; CFE,
camomile flowers extract (n=12-14).
doi: 10.1371/journal.pone.0080335.g004
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Figure 5.  Prevention of insulin resistance and dyslipidemia by camomile flowers extract during HFD-feeding of healthy
C57BL/6 mice.  (A) Fasting plasma glucose of LFD-fed, untreated HFD-fed or HFD-fed mice treated for 20 weeks with CFE (n=14/
group). (B) Fasting plasma insulin after 20 weeks of intervention (LFD n=7, HFD n=14, HFD+CFE n=14). (C) Effect of 20 weeks
preventive feeding on homeostatic model assessment of insulin resistance (HOMA-IR) index (LFD n=7, HFD n=13, HFD+CFE
n=12). AUC, area under the curve. (D) Fasting plasma NEFA after 20 weeks of treatment (LFD n=8, HFD n=10, HFD+CFE n=9). (E)
Fasting plasma triacylglycerol after 20 weeks of treatment (LFD n=8, HFD n=14, HFD+CFE n=14). Data are expressed as mean ±
SEM. n.s. not significant, *p≤0.05, **p≤0.01 vs. untreated HFD-fed mice. LFD, low-fat diet; HFD, high-fat diet; CFE, camomile
flowers extract.
doi: 10.1371/journal.pone.0080335.g005
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Figure 6.  Prevention of non-alcoholic fatty liver disease (NAFLD) by camomile flowers extract during HFD-feeding of
healthy C57BL/6 mice.  (A) Plasma levels of liver alanine transaminase (ALT) after 20 weeks of treatment (n=12/group). (B) Effect
treatment over 20 weeks on liver morphology. (C, D) Liver concentrations of triacylglycerol and NEFA after 20 weeks of treatment
(n=10-12/group). (E) TNFα protein concentrations in liver (n=9/group). (F) Liver qPCR analysis of genes involved in lipid metabolism
(n=4-6 pools, 2 mice/pool). (G) Liver qPCR analysis of genes involved in inflammation and macrophage infiltration (n=4-6 pools, 2
mice/pool). Data are expressed as mean ± SEM. n.s. not significant, *p≤0.05, **p≤0.01 vs. untreated HFD-fed mice. LFD, low-fat
diet; HFD, high-fat diet; CFE, camomile flowers extract.
doi: 10.1371/journal.pone.0080335.g006
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Discussion
Chamomile is a popular herb that has been used for
thousands of years in ancient Egypt, Greece, and Rome [30].
Its phytomedicinal application is mainly predicated on its
antioxidant, antiinflammatory, antiseptic, antispasmodic and
wound-healing effects [32], especially in gastrointestinal
disorders [19,33]. To our knowledge, only few studies showed
antidiabetic effects of diverse, mainly water chamomile
extracts, and the underlying mechanisms of action are still
poorly understood. Furthermore, there are so far no studies on
the effects of chamomile flowers extracts in diet-induced
obesity (DIO) mice, one of the most often applied standard
models for the formation of insulin resistance.
Cemek et al. investigated the effects of an ethanolic extract
of Matricaria chamomilla in streptozotocin (STZ)-induced
diabetic rats, and observed significant reductions in blood
glucose after 7 to 14 days with 50-100 mg/kg/d extract
administered orally [34]. Kato et al. [35] tested instead of
ethanolic, hot water chamomile extracts and major constituents
in STZ-induced diabetic rats, and they observed decreased
hyperglycaemia with 500 mg/kg/d orally applied extract.
Eddouks et al. reported that aqueous extracts of the
taxonomically related Chamaemelum nobile reduced blood
glucose levels after 2 weeks of 20 mg/kg/d extract dosing in
normal and STZ-induced rats [36]. Additionally, Gupta et al.
could observe hepatoprotective effects with chamomile extracts
in Paracetamol-intoxicated rats [37]. However, all these studies
could not sufficiently shed light on the underlying molecular
mechanisms of the observed physiological effects.
Due to their nature as nutrient-sensors the PPARs are
interesting targets for dietary intervention and treatment of
metabolic disorders with plant-derived mixtures of natural
products. In this study, we focused on the antidiabetic and
hypolipidemic effects and the interaction of ethanolic
chamomile flowers extract (CFE) with two important subtypes
of the peroxisome proliferator-activated receptors, namely
PPARγ and PPARα. Activation of PPARγ, a key ligand-
dependent transcriptional regulator of adipocytes, is a well-
known approach for systemically improving insulin sensitivity,
whereas activation of PPARα in the liver is efficient to
counteract metabolic disorders of this organ and indirectly
alleviates a number of other complex disorders including
plasma cholesterol levels or insulin resistance [29]. PPARβ/δ is
much more ubiquitously expressed in many diverse cells than
the other two PPAR subtypes, and its potential impact in a
Figure 7.  Camomile flowers extract (CFE) does not induce adverse effects commonly linked with PPAR agonists.  (A)
Effect of CFE on cellular viability in human HepG2 cells after treatment for 24 h. Data are expressed as mean ± SD (n=3/group). (B,
C) Mouse body weight during treatment of DIO mice for 6 weeks with CFE or HFD alone (B) and during the preventive study by 20
weeks feeding of healthy C57BL/6 mice with LFD, HFD alone or HFD with CFE (C). Data are expressed as mean ± SEM (n=14/
group). Data are shown as mean ± SEM. (D, E) Food intake during treatment of DIO mice for 6 weeks with CFE or HFD alone (D)
and during the preventive study by 20 weeks feeding of healthy C57BL/6 mice with LFD, HFD alone or HFD with CFE (E). Data are
expressed as mean ± SEM (n=14/group). (F) Hematocrit of treated DIO mice after 6 weeks (mean ± SEM, n=14/group). (G) Effect
of CFE on plasma osteocalcin levels after treatment of DIO mice for 6 weeks (mean ± SEM, n=14/group). *p≤0.05, n.s. not
significant vs. untreated HFD-fed mice. LFD, low-fat diet; HFD, high-fat diet; CFE, camomile flowers extract.
doi: 10.1371/journal.pone.0080335.g007
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cellular or physiological context is consequently difficult to
pinpoint. PPAR-activating molecules such as the
thiazolidinediones (PPARγ agonists) and the fibrates (PPARα
agonists) have been widely applied as drugs since the 1990s
and 1960s, respectively [38]. More recently, ligands with partial
instead of full PPAR activation (SPPARMs) have been
proposed to exert strong metabolic effects with potentially
fewer side effects [14,39,40].
Consequently, dosing of high-fed diet (HFD)-fed obese mice
with CFE alleviated insulin resistance approximately half as
effective as RGZ, and further strongly reduced plasma NEFA
and triacylglycerol similar to RGZ. Additionally, CFE decreased
hypercholesterolemia and prevented the development of non-
alcoholic fatty liver disease (NAFLD) and hepatic inflammation.
These effects of CFE were not observed with the specific
PPARγ activator RGZ, suggesting additional effects from
activating PPARs in liver. The observed hypocholesterolemic
and hepatoprotective combined with antidiabetic effects are
shared with other PPAR pan agonists such as the fibrates or
the amorfrutins, suggesting similar molecular mechanisms
based on synergistic activation of PPARγ and PPARα [20,31].
Future in-depth analyses are needed to better understand
the complex beneficial effects of the CFE. Such studies may
include the role of transcriptional control of all three PPAR
subtypes or studying additional peripheral metabolic target
tissues. Without doubt, the pathophysiology of metabolic
diseases as well as the pharmacological intervention thereof
are based on complicated networks of metabolic events
(carbohydrate/lipid digestion and uptake, storage, distribution,
breakdown, neogenesis, excretion) and diverse tissues (e.g.
pancreas, adipose, liver, skeletal muscle, macrophages) [28],
and modulation of PPARs by natural products in plant extracts
is only one aspect of the underlying mechanism(s) of action.
Other possible targets of chamomile extracts might also be
involved in the observed antidiabetic effects. For instance, Kato
et al. [35] tested hot water chamomile extracts and major
constituents in vitro on α-Amylase, intestinal α-Glucosidase,
hepatic glycogen phosphorylase, aldose reductase and sorbitol
dehydrogenase activity, which all have important roles in
carbohydrate absorption or metabolism. These authors
observed IC50 values ranging from 17 µg/ml to 5200 µg/ml,
which is partly in the range of the affinity binding constants and
EC50 values that we observed here for the PPARs. The
complex CFE plant extract may thus contain many active
ingredients addressing multiple targets relevant for the
metabolic syndrome.
Extracts of chamomile flowers contain a vast amount of
detectable chemical constituents, and more than 100 different
natural products have been identified so far, including
flavonoids, sesquiterpenes and their derivatives,
monoterpenes, coumarins and phenolic acids [19,30,35,41].
Many of these small molecules, predominantly the flavonoids,
have already been identified as PPAR ligands, including
genistein [42], daidzein [42], biochanin A [42,43], formononetin
[42], glycitein [42], apigenin [43,44], chrysin [44], kaempferol
[44] [43], quercetin [43,45] luteolin [43,46], diosmetin [43], and
naringenin [43,47]. As in chamomile flowers the flavonoid class
comprises more than 60% of the secondary phytochemical
compounds [19], it seems futile to search for the specific PPAR
agonist. It is rather probably the synergistic action of many
flavonoids and other small molecules that mediate activation of
nutrient-sensing PPARs and the antidiabetic, antiinflammatory
and antihyperlipidemic effects of chamomile flowers extracts
observed in this study. Besides PPARγ and its PPAR subtypes,
other biological targets might be involved in the metabolic
improvements observed in our mice studies. For instance,
esculetin and quercetin, two major constituents of CFE, inhibit
intestinal α-Glucosidases activities and reduce blood glucose in
STZ-diabetic rats [35]. Luteolin and quercetin were shown to
inhibit hepatic glycogen phosphorylase and increase liver
glycogen content [35]. Chlorogenic acid, a phenolic acid
present in chamomile flowers, may slow down carbohydrate
absorption by inhibiting intestinal glucose transport [48].
Additional important effects of polyphenols comprise
antioxidant activity, attenuating endoplasmic reticulum stress
and repressing proinflammatory pathways [49].
As shown here, CFE seems to contain a set of numerous
unidentified, more or less potent PPAR ligands of different
chemical structure. The large binding pocket of the PPARs
allows for promiscuous binding of ligands with large structural
diversity [4]. We suggest that CFE allows for
polypharmacological, synergistic modulation of PPARs and
potentially a number of so far unexplored targets to influence
various metabolic pathways, resulting in the beneficial
physiological effects observed in this study (Figure 8). The
multidrug/multitarget principle applied in this study is very
difficult to pinpoint mechanistically in all details. But on the
other hand this rather holistic approach may to some degree
fulfill much better the polyetiological background of the
metabolic syndrome than the reductionist approach of selective
single-drug/single-target interventions, in particular for
developing efficient preventive strategies to counteract age-
associated metabolic diseases. Holistic approaches that make
use of edible traditional plant extracts or active fractions thereof
may effectively address early on dysregulated biological
pathways, and minimize the risk of adverse side-effects.
Furthermore, from a technical point of view, plant extracts do
not require expensive isolation and enrichment of single
compounds from complex mixtures or sophisticated chemical
syntheses of active small molecules. Clearly, cultivation
conditions and standardization of extract preparation are
important but technically feasible issues.
In our mice studies the extract dose was 200 mg/kg per day,
dissolved in drinking water (1-2 mg/ml) administered evenly
throughout the day. For a human equivalent dose of
20 mg/kg/d and mean body weight of 80 kg the daily dose
would be approximately 1600 mg extract. This amount could be
reached for example with 2 to 4 cups of tea preparations (2-4
mg/ml) daily, which is a reasonable amount for dietary
intervention. Clearly, solvent and extraction conditions will
influence composition and stability of the extract. Time of intake
could be a critical point, since chamomile extracts might inhibit
intestinal carbohydrate uptake and transport [35] that is crucial
particularly during or immediately after meal consumption.
Furthermore, the circadian changes of nuclear receptors
activation may influence the efficiency of the ingredients of the
Antidiabetic Effects of Chamomile Flowers Extract
PLOS ONE | www.plosone.org 13 November 2013 | Volume 8 | Issue 11 | e80335
Figure 8.  Concept of PPAR polypharmacology.  Ethanolic extracts of chamomile flowers represent a complex mixture of plenty
diverse compounds, particularly small molecules. In dependance of their bioavailability, a set of small molecules bind to peroxisome
proliferator-activated receptors (PPARs) and potentially other yet unidentified targets. Ligand-binding then induces conformational
changes in PPARs that lead to their transcriptional activation/modulation and thus to beneficial regulation of glucose and lipid
metabolism. In summary, the polypharmacological mechanism is driven by the composition of structurally diverse small molecules in
chamomile flowers extracts and by the large binding pocket of PPARs leading to promiscuous ligand-binding properties. The
proportion of activation between the different PPAR subtypes is determined by the cellular context (e.g. cell type) and by the definite
chemical composition of the plant extract.
doi: 10.1371/journal.pone.0080335.g008
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CFE [50]. In general, CFE is a safe and widely used extract
that can be readily applied for humans. Future clinical studies
may validate the observed antidiabetic and antihyperlipidemic
effects of CFE to provide the basis for the development of
efficient functional foods or nutraceuticals.
As demonstrated here, the application of plant-derived
extracts as selective gene expression activators highlights the
unique biological properties of natural resources to counteract
metabolic diseases, and suggests that tailored dietary
intervention may represent a fruitful approach for alleviating
common diseases.
Supporting Information
Figure S1.  Gene expression in white adipose tissue of
camomile flowers extract-treated DIO mice. Visceral white
adipose tissue of insulin-resistent DIO mice treated for 6 weeks
with either HFD, HFD+RGZ or HFD+CFE was analysed by
qPCR and is presented relative to untreated HFD-fed mice. (A)
Genes involved in lipid metabolism. (B) Genes involved in
inflammation and macrophage infiltration. Data are expressed
as mean ± SEM (n=4-6 pools, 2 mice/pool). n.s. not significant,
*p≤0.05, **p≤0.01 vs. untreated HFD-fed mice.
(TIF)
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